Abstract:Drug shortages occur when demand exceeds supply, a simple description behind which hides a multiplicity of causes. Demand can exceed supply because demand rises, supply falls, or both, or because they both rise and fall but out of proportion to one another. Making matters even more complicated, a shortage can exist because supply and demand are moving differently in different parts of the country, creating an uneven map of problems accessing essential medications. During the COVID-19 pandemic, many of these scenarios played out simultaneously. 1 Demand surged unevenly across the country as waves of disease hit metropolitan and rural areas, manufacturing constraints affected both domestic and foreign suppliers, and lockdowns and export bans challenged the distribution of pharmaceutical supplies. Together, these various factors placed an enormous strain on the US pharmaceutical supply chain, revealing the key vulnerabilities of a system chronically prone to failures. Indeed, drug shortages have been plaguing the US health care system for years, with hundreds of drugs being listed as in shortage at any point in time. Shortages may drive patients to skip doses, use less than prescribed, or forego needed treatments altogether. Hospitals and clinicians also must bear the cost of shortages, including identifying and implementing possible therapeutic substitutions, often with less clinically effective or less safe options. Drug shortages therefore not only have large costs to clinicians, hospitals, supply chain participants, patients, and families, but also have an immense impact on patients' lives and quality of life. Drug shortages are one of the key areas highlighted in the President Biden's Executive Order on America's Supply Chains 2 and have been the focus of recent congressional debate, including in hearings by the Senate Finance Committee in December 2023 and the House Ways and Means Committee in February 2024. The study by Callaway Kim and colleagues 3 examines 1 type of drug shortage: the shortage caused by a drop in supply, as measured by a reduction in pharmaceutical sales. Starting from supply chain issue reports recorded by the US Food and Drug Administration (FDA) and the American Society of Health-Systems Pharmacists (ASHP) between 2017 and 2021, Callaway Kim et al 3 examined whether drugs with supply chain issue reports were more likely to have decreases of 33% or more in sales in the 6-month period following the reports compared with a control group of matched drugs without supply chain issue reports. After adjusting for drug characteristics, Callaway Kim et al 3 found that drugs with supply chain issue reports were more than 3 times more likely to experience sharp declines in sales compared with matched drugs without reports in the pre–COVID-19 period (13.7% [95% CI, 10.4%-17.8%] vs 4.1% [95% CI, 3.6%-4.8%]). Callaway Kim et al 3 also found that these supply shortages were more frequent for both drug types at the start of the pandemic (34.2% of drugs with supply chain issue reports vs 9.5% for those without; marginal odds ratio, 4.9 [95% CI, 2.1-11.6]) than after May 2020 (9.8% vs 3.6%; marginal odds ratio, 2.9 [95% CI, 1.6-5.3]). In line with the literature on this topic, Callaway Kim et al 3 found that supply chain issue reports are more common with generic drugs and their correlates, including older products, drugs with at least 5 manufacturers, and drugs categorized as essential medicines by the World Health Organization. Interestingly, Callaway Kim et al 3 found that having a supply chain issue report was less of a signal associated with an impending shortage for some of these drugs, possibly because those drugs had higher likelihoods of shortages even without a supply chain issue report. Shortages of these medications, often critical for caring for patients with cancer and other chronic illnesses, continue to bedevil the health care system. According to the FDA and the Government Accountability Office, production problems, such as those studied by Callaway Kim et al, 3 are responsible for 70% or more of recorded shortages. 4 ,5 However, the surveillance system that detects shocks to pharmaceutical supply is heavily focused on capturing production information, leaving the cases of demand-driven shortages and distribution problems underidentified. The Federal Food, Drug, and Cosmetic Act requires drug manufacturers to notify the FDA of any manufacturing problems that may lead to meaningful disruptions in the supply of the drugs they produce, allowing the FDA to work with the manufacturer to mitigate or prevent reductions in supply. By statute, the FDA must publish a Drug Shortage List, one of the primary data sources in the study by Callaway Kim and colleagues, 3 which represents the list of drugs for which the FDA has receiv -Abstract Truncated-

Pharmaceutical supply chain reliability and effects on drug shortages

Mitigating the impact of drug shortages for a healthcare facility: An inventory management approach

Effects of Geopolitical Strain on Global Pharmaceutical Supply Chain Design and Drug Shortages

Minimization of Drug Shortages in Pharmaceutical Supply Chains: A Simulation-Based Analysis of Drug Recall Patterns and Inventory Policies

Drug Shortages—A Study in Complexity

Drug Shortages Prior to and During the COVID-19 Pandemic

Drug shortage management: A qualitative assessment of a collaborative approach

The benefits (or detriments) of adapting to demand disruptions in a hospital pharmacy with supply chain disruptions

Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them

Enhancing Pharmaceutical Supply Chain Resilience: A Multi-Objective Study with Disruption Management

Contemporary Perspective on Supply Chain Management Regarding Drug Sourcing Shortages

Predicting pharmaceutical supply chain disruptions before and during the COVID‐19 pandemic

Optimization of Inventory Management to Prevent Drug Shortages in the Hospital Supply Chain

Comparing Drug Shortages Experienced by Institutions With National Metrics

Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services

Factors Influencing Drug Shortages and Their Resolution in South Korean Community Pharmacies

Effectiveness of Supply Chain Planning in Ensuring Availability of CD/NCD Drugs in Non-Metropolitan and Rural Public Health System

Critical drug shortages: implications for emergency medicine

Adapting to Disruptions: Flexibility as a Pillar of Supply Chain Resilience

When Should the FDA Inspect Pharmaceutical Manufacturing Facilities to Better Mitigate Drug Shortages?

Reasons for supply side driven drug shortages - A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders